MX2010008518A - Ciertas entidades quimicas, composiciones y metodos. - Google Patents

Ciertas entidades quimicas, composiciones y metodos.

Info

Publication number
MX2010008518A
MX2010008518A MX2010008518A MX2010008518A MX2010008518A MX 2010008518 A MX2010008518 A MX 2010008518A MX 2010008518 A MX2010008518 A MX 2010008518A MX 2010008518 A MX2010008518 A MX 2010008518A MX 2010008518 A MX2010008518 A MX 2010008518A
Authority
MX
Mexico
Prior art keywords
skeletal
methods
muscle
chemical entities
certain chemical
Prior art date
Application number
MX2010008518A
Other languages
English (en)
Spanish (es)
Inventor
Gustave Bergnes
Luke W Ashcraft
Jianchao Wang
Bradley P Morgan
Alex Muci
Zhe Yang
Scott Collibee
Jeff Gardina
Brian Stoltz
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MX2010008518A publication Critical patent/MX2010008518A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
MX2010008518A 2008-02-04 2009-02-02 Ciertas entidades quimicas, composiciones y metodos. MX2010008518A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2606708P 2008-02-04 2008-02-04
PCT/US2009/000686 WO2009099594A1 (en) 2008-02-04 2009-02-02 Certain chemical entities, compositions and methods

Publications (1)

Publication Number Publication Date
MX2010008518A true MX2010008518A (es) 2010-11-10

Family

ID=40952391

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008518A MX2010008518A (es) 2008-02-04 2009-02-02 Ciertas entidades quimicas, composiciones y metodos.

Country Status (18)

Country Link
US (2) US7989469B2 (enExample)
EP (1) EP2244711A4 (enExample)
JP (1) JP2011510985A (enExample)
KR (1) KR20100119773A (enExample)
CN (1) CN101983061A (enExample)
AR (1) AR072242A1 (enExample)
AU (1) AU2009210787A1 (enExample)
BR (1) BRPI0907502A2 (enExample)
CA (1) CA2713864A1 (enExample)
CL (1) CL2009000246A1 (enExample)
CO (1) CO6290673A2 (enExample)
EA (1) EA201001224A1 (enExample)
EC (2) ECSP10010430A (enExample)
IL (1) IL207367A0 (enExample)
MX (1) MX2010008518A (enExample)
TW (1) TW200946524A (enExample)
WO (1) WO2009099594A1 (enExample)
ZA (1) ZA201005780B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CN101983061A (zh) * 2008-02-04 2011-03-02 赛特凯恩蒂克公司 某种化学物质、组合物和方法
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
EP2730575B1 (en) * 2011-07-09 2015-09-16 Xuanzhu Pharma Co., Ltd. Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
US10272082B2 (en) 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
EA032480B1 (ru) * 2012-04-11 2019-06-28 Сайтокинетикс, Инк. Способы повышения устойчивости скелетных мышц к утомлению
PL3137622T3 (pl) 2014-04-29 2022-05-09 Cytokinetics, Inc. Sposoby redukowania spadku pojemności życiowej
TW201927738A (zh) * 2017-12-14 2019-07-16 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物
TWI794369B (zh) * 2017-12-14 2023-03-01 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物
WO2020240586A1 (en) * 2019-05-28 2020-12-03 Mankind Pharma Ltd. Novel compounds for inhibition of janus kinase 1
EP4333982A1 (en) * 2021-05-06 2024-03-13 Exscientia Al Limited Pkc-theta modulators
CN118702622A (zh) * 2024-08-30 2024-09-27 阜新达得利化工股份有限公司 一种3-溴-2-氰基吡啶的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
CN1816530A (zh) 2003-07-01 2006-08-09 麦克公司 用于治疗高眼压症的眼用组合物
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
AU2005208938A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Anti-viral therapeutics
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
DK2069352T5 (en) 2006-08-02 2017-04-03 Cytokinetics Inc SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
US7981893B2 (en) 2006-10-19 2011-07-19 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
EP2139478A4 (en) 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
CN101983061A (zh) * 2008-02-04 2011-03-02 赛特凯恩蒂克公司 某种化学物质、组合物和方法
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use

Also Published As

Publication number Publication date
BRPI0907502A2 (pt) 2019-01-15
IL207367A0 (en) 2010-12-30
AR072242A1 (es) 2010-08-18
EP2244711A1 (en) 2010-11-03
AU2009210787A1 (en) 2009-08-13
JP2011510985A (ja) 2011-04-07
US20090253737A1 (en) 2009-10-08
KR20100119773A (ko) 2010-11-10
CA2713864A1 (en) 2009-08-13
CL2009000246A1 (es) 2009-06-26
CO6290673A2 (es) 2011-06-20
US20110312975A1 (en) 2011-12-22
TW200946524A (en) 2009-11-16
ECSP10010432A (es) 2011-01-31
EP2244711A4 (en) 2011-08-24
WO2009099594A1 (en) 2009-08-13
EA201001224A1 (ru) 2011-08-30
ECSP10010430A (es) 2011-02-28
ZA201005780B (en) 2011-04-28
US7989469B2 (en) 2011-08-02
CN101983061A (zh) 2011-03-02

Similar Documents

Publication Publication Date Title
WO2008016648A3 (en) Certain chemical entities, compositions and methods
ECSP10010430A (es) Ciertas Entidades Químicas, Composiciones y Procedimientos
MX2009001170A (es) Determinadas entidades quimicas, composiciones y metodos.
AU2019268177A1 (en) Improving resistance to skeletal muscle fatigue
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
JO3469B1 (ar) طافرات fgf21 واستخداماتها
EA201990619A1 (ru) Fgf21 мутанты и их применение
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
EA024751B8 (ru) Мутанты fgf21 и их применение
UA104605C2 (uk) Аналоги глюкагону
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
BR112015024846A2 (pt) composições para utilização no estímulo do crescimento ósseo
GEP20146056B (en) Acylated glucagon analogues
BRPI0606256A2 (pt) inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
MX2010001692A (es) Ciertas entidades quimicas, composiciones y metodos.
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
PL2021337T3 (pl) Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
MX2009010049A (es) Metodos y composiciones para promover la salud de huesos y articulaciones.
MX2009003206A (es) Composiciones semejantes a azeotropo de 2-cloro-3,3,3,-trifluoropr open (hcfc-1233xf y 2-cloro-1,1,1,2-tetrafluoropropano (hcfc-244bb).
EA019744B9 (ru) Изотиазолилоксифениламидины и их применение для борьбы с фитопатогенными грибами и семенной материал, обработанный изотиазолилоксифениламидинами
CL2007001886A1 (es) Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.
MX2014007719A (es) Derivados de amida ciclica como inhibidores de 11 -beta-hidroxiesteroide deshidrogenasa y los usos de los mismos.
UY31877A (es) Péptidos específicos de los receptores de melanocortina para el tratamiento de la obesidad / 669
WO2010051327A3 (en) Azeotrope-like compositions of 1,1,2,3-tetrachloropropene and hydrogen fluoride

Legal Events

Date Code Title Description
FA Abandonment or withdrawal